What is claimed is:

1. A stent comprising an effective amount of a JNK Inhibitor.

2. The stent of claim 1 having a coating comprising an effective amount of a JNK Inhibitor.

3. The stent of claim 1 comprising a material having an effective amount of a JNK Inhibitor incorporated therein.

4. The stent according to claim 1, wherein the JNK Inhibitor has the following formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

R_1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently from R_3;

R_2 is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$,$-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

a is 1, 2, 3, 4, 5 or 6;

b and *c* are the same or different and at each occurrence independently 0, 1, 2, 3 or 4;

d is at each occurrence 0, 1 or 2;

R_3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, heterocycle, heterocycloalkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_4 is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently from R_3, or R_4 is halogen or hydroxy;

R_5, R_6 and R_7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R_5, R_6 and R_7 are optionally substituted with one to four substituents independentlyfrom R_3; and R_8 and R_9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R_8 and R_9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R_8, R_9, and R_8 and R_9 taken together to form a heterocycle are optionally substituted with one to four substituents independently from R_3.

5. The stent according to claim 1, wherein the JNK Inhibitor has the following formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein:

R_1 is aryl or heteroaryl optionally substituted with one to four substituents independently from R_7;

R_2 is hydrogen;

R_3 is hydrogen or lower alkyl;

R_4 represents one to four optional substituents, wherein each substituent is the same or different and independently halogen, hydroxy, lower alkyl or lower alkoxy;

R_5 and R_6 are the same or different and independently $-R_8$, $-(CH_2)_aC(=O)R_9$, $-(CH_2)_aC(=O)OR_9$, $-(CH_2)_aC(=O)NR_9R_{10}$, $-(CH_2)_aC(=O)NR_9(CH_2)_bC(=O)R_{10}$, $-(CH_2)_aNR_9C(=O)R_{10}$, $(CH_2)_aNR_{11}C(=O)NR_9R_{10}$, $-(CH_2)_aNR_9R_{10}$, $-(CH_2)_aOR_9$, $-(CH_2)_aSO_cR_9$ or $-(CH_2)_aSO_2NR_9R_{10}$;

or R_5 and R_6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;

R_7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, $-C(=O)OR_8$, $-OC(=O)R_8$, $-C(=O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_cR_8$, $-SO_cNR_8R_9$, $-NR_8SO_cR_9$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

R_8, R_9, R_{10} and R_{11} are the same or different and at each occurrence independently hydrogen, alkyl, substituted alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl;

or R_8 and R_9 taken together with the atom or atoms to which they are attached to form a heterocycle;

a and *b* are the same or different and at each occurrence independently 0, 1, 2, 3 or 4; and

c is at each occurrence 0, 1 or 2.

6. The stent according to claim 1, wherein the JNK Inhibitor has the following formula:



or a pharmaceutically acceptable salt, solvate or stereoisomer thereof,

wherein R_0 is -O-, -S-, -S(O)-, -$S(O)_2$-, NH or -CH_2-;

the compound being (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;

the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position, wherein the first and second substituent, when present, are independently alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by formula (a), (b), (c), (d), (e), or (f):



wherein R_3 and R_4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R_3 and R_4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and

R_5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl.

7. The stent according to claim 2 wherein the coating comprises a pharmaceutically acceptable carrier.

8. The stent according to claim 1 wherein the stent is a stent graft.

9. The stent according to claim 1 wherein the stent comprises a polymer.

10. The stent according to claim 9 in which the polymer is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluorethylene, a polymethylmethacrylate, a polyethylene, a poly(ethylene terephthalate), a polyalkylene oxalate, a polyurethane, a polysiloxane, a poly(dimethyl siloxane), a polycyanoacrylate, a polyphosphazene, a poly(amino acid), a ethylene glycol

I dimethacrylate, a poly(methyl methacrylate), a poly(2-hydroxyethyl methacrylate), a poly(HEMA),or a polyhydroxyalkanoate compound.

11. The stent according to claim 2 wherein the coating is a controlled-release coating.

12. A method for making the stent of claim 2, comprising the step of coating a stent with an effective amount of a JNK Inhibitor.

13. The method according to claim 12 wherein the stent is a stent graft.

14. The stent according to claim 3 wherein the material having an effective amount of a JNK Inhibitor incorporated therein allows for controlled-release of the JNK Inhibitor.

15. A method for making the stent of claim 3, comprising manufacturing a stent with material having an effective amount of a JNK Inhibitor incorporated therein.

16. A method for treating or preventing a cardiovascular or renal disease in a patient, comprising implanting the stent of claim 1 into a patient in need thereof.

17. A method for treating or preventing atherosclerosis in a patient, comprising implanting the stent of claim 1 into a patient in need thereof.

18. The method of claim 16 further comprising surgical intervention.

19. The method of claim 17 further comprising surgical intervention.

20. The method of claim 18 wherein the surgical intervention involves percutaneous coronary intervention, revascularization, percutaneous transluminal coronary angioplasty, carotid percutaneous transluminal angioplasty coronary by-pass grafting or coronary angioplasty with stent implantation.

21. The method of claim 18 wherein the surgical intervention involves renal angioplasty; peripheral percutaneous transluminal intervention of the iliac, femoral or popliteal arteries; or surgical intervention using impregnated artificial grafts.

22. The method of claim 16 wherein the stent is a stent graft.

23. The method of claim 17 wherein the stent is a stent graft.

24. The method of claim 20 wherein the implanting occurs prior to the administration of angioplasty.

25. The method of claim 20 wherein the implanting occurs during the administration of angioplasty.

26. The method of claim 20 wherein the implanting occurs after the administration of angioplasty.

27. A kit comprising the stent of claim 1 and directions for its use.